Do you want to read an article? Please log in or register.
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial
Lung Cancer
![](https://cdn.healthbook.network/wp-content/uploads/2018/03/like_hb.png)